ProSciento, Inc and Antaros to partner and launch functional imaging studies of cardiometabolic drug action

closer lookProSciento, Inc and Antaros Medical recently announced a strategic collaboration to study the action of cardiometabolic drugs and drug candidates using PET/MRI imaging. The initiative will focus on diabetes, obesity, and non-alcoholic fatty liver disease (NAFLD), including nonalcoholic steatohepatitis (NASH).

Read full article at Close Concerns »

Stay Connected

Would you like to receive updates from ProSciento?

I'm interested in receiving: